Pharmacological validation of a chronic social stress model of depression in rats: Effects of reboxetine, haloperidol and diazepam

Behavioural Pharmacology

Volumn 19, Issue 3, 2008, Pages 183-196

  Rygula, Rafal ^a,b,c   Abumaria, Nashat ^b,c   Havemann Reinecke, Ursula ^a,c   Rüther, Eckart ^a,c   Hiemke, Christoph ^d   Zernig, Gerald ^e   Fuchs, Eberhard ^a,b,c   Flügge, Gabriele ^b,c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b GERMAN PRIMATE CENTER   (Germany)

^c CMPB (Center for Molecular Physiology of the Brain)   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Animal model; Antidepressant; Depression; Diazepam; Haloperidol; Rat; Reboxetine; Stress

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DIAZEPAM; HALOPERIDOL; NEUROLEPTIC AGENT; REBOXETINE; SUCROSE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SELECTIVITY; FEMALE; FORCED SWIMMING TEST; IMMOBILIZATION; LOCOMOTION; MALE; MAZE TEST; MOTIVATION; NONHUMAN; RAT; REWARD; SOCIAL STRESS;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DIAZEPAM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; MORPHOLINES; MOTIVATION; MOTOR ACTIVITY; RATS; RATS, WISTAR; REWARD; STRESS, PSYCHOLOGICAL;

EID: 43449112081     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3282fe8871     Document Type: Article

References (71)

1. Antelman SM, Kocan D, Edwards DJ, Knopf S (1987). A single injection of diazepam induces long-lasting sensitization. Psychopharmacol Bull 23:430-434.
2. Baumann P, Hiemke C, Ulrich S, Gaertner I, Rao ML, Eckermann G, Gerlach M, et al. (2004). Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit 26:167-170.
3. Borowski TB, Kokkinidis L (1992). Long-term influence of D-amphetamine on mesolimbic brain-stimulation reward: comparison to chronic haloperidol and naloxone effects. Pharmacol Biochem Behav 43:1-15.
4. Connor TJ, Kelliher P, Harkin A, Kelly JP, Leonard BE (1999). Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat. Eur J Pharmacol 379:125-133.
5. Coventry TL, D'Aquila PS, Brain P, Willner P (1997). Social influences on morphine conditioned place preference. Behav Pharmacol 8:575-584.
6. Cryan JF, Page ME, Lucki I (2002). Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur J Pharmacol 436:197-205.
7. Dailly E, Hascoet M, Colombel MC, Jolliet P, Bourin M (2002). Relationship between cerebral pharmacokinetics and anxiolytic activity of diazepam and its active metabolites after a single intra-peritoneal administration of diazepam in mice. Hum Psychopharmacol 17:239-245.
8. Dalterio S, Bartke A (1979). Perinatal exposure to cannabinoids alters male reproductive function in mice. Science 205:1420-1422.
9. Dawson GR, Tricklebank MD (1995). Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol Sci 16:33-36.
10. Delfs JM, Zhu Y, Druhan JP, Aston-Jones GS (1998). Origin of noradrenergic afferents to the shell subregion of the nucleus accumbens: anterograde and retrograde tract-tracing studies in the rat. Brain Res 806:127-140.
11. Dostert P, Benedetti MS, Poggesi I (1997). Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 7 (Suppl 1):S23-S35; discussion S71-S73.
12. Duncan GE, Paul IA, Harden TK, Mueller RA, Stumpf WE, Breese GR (1985). Rapid down regulation of beta adrenergic receptors by combining antidepressant drugs with forced swim: a model of antidepressant-induced neural adaptation. J Pharmacol Exp Ther 234:402-408.
13. Edwards DM, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, et al. (1995). Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos 16:443-460.
14. Fernandes C, Arnot MI, Irvine EE, Bateson AN, Martin IL, File SE (1999). The effect of treatment regimen on the development of tolerance to the sedative and anxiolytic effects of diazepam. Psychopharmacology (Berl) 145:251-259.
15. Flugy A, Gagliano M, Cannizzaro C, Novara V, Cannizzaro G (1992). Antidepressant and anxiolytic effects of alprazolam versus the conventional antidepressant desipramine and the anxiolytic diazepam in the forced swim test in rats. Eur J Pharmacol 214:233-238.
16. Fuchs E, Flugge G (2002). Social stress in tree shrews: effects on physiology, brain function, and behavior of subordinate individuals. Pharmacol Biochem Behav 73:247-258.
17. Gorka Z, Janus K (1985). Effects of neuroleptics displaying antidepressant activity on behavior of rats in the forced swimming test. Pharmacol Biochem Behav 23:203-206.
18. Gorman JM, Papp LA (2000). Efficacy of venlafaxine in mixed depression-anxiety states. Depress Anxiety 12 (Suppl 1):77-80.
19. Handley SL, Mithani S (1984). Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch Pharmacol 327:1-5.
20. Harkin A, Kelly JP, McNamara M, Connor TJ, Dredge K, Redmond A, Leonard BE (1999). Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur J Pharmacol 364:123-132.
21. Hartter S, Weigmann H, Hiemke C (2000). Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. J Chromatogr B Biomed Sci Appl 740:135-140.
22. Janssen PA (1967). The pharmacology of haloperidol. Int J Neuropsychiatry 3 (Suppl 1):10-18.
23. Kawashima K, Araki H, Aihara H (1986). Effect of chronic administration of antidepressants on duration of immobility in rats forced to swim. Jpn J Pharmacol 40:199-204.
24. Keeney AJ, Hogg S (1999). Behavioural consequences of repeated social defeat in the mouse: preliminary evaluation of a potential animal model of depression. Behav Pharmacol 10:753-764.
25. Kitada Y, Miyauchi T, Kanazawa Y, Nakamichi H, Satoh S (1983). Involvement of alpha- and beta 1-adrenergic mechanisms in the immobility-reducing action of desipramine in the forced swimming test. Neuropharmacology 22:1055-1060.
26. Koolhaas JM HPM, Kemperman C, Bohus B, van den Hoofdakker RH, Beersma DGM (1990). Single social defeat in male rats induces a gradual but long lasting behavioural change: a model of depression? Neurosci Res Comm 7:35-41.
27. Kudriavtseva NN, Bakshtanovskaia IV, Madorskaia IA, Popova NK, Marona-Lewicka D, Vetulani I (1992). Experimental model of depression: neurochemical changes and the effects of imipramine and citalopram. Zh Nevropatol Psikhiatr Im S S Korsakova 92:106-109.
28. Linner L, Endersz H, Ohman D, Bengtsson F, Schalling M, Svensson TH (2001). Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther 297:540-546.
29. Lu TY, Kupa A, Easterbrook G, Mangoni AA (2005). Profound weight loss associated with reboxetine use in a 44-year-old woman. Br J Clin Pharmacol 60:218-220.
30. Lynch MR (1990). Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol. Neuropsychobiology 24:102-108.
31. Magnus-Ellenbroek B Havemann-Reinecke U (1993). Morphine-induced hyperactivity in rats - a rebound effect? Naunyn Schmiedebergs Arch Pharmacol 347:635-642.
32. Mao J, Price DD, Caruso FS, Mayer DJ (1996). Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats. Pain 67:361-368.
33. Marti J, Armario A (1993). Effects of diazepam and desipramine in the forced swimming test: influence of previous experience with the situation. Eur J Pharmacol 236:295-299.
34. Miczek KA (1991). Tolerance to the analgesic, but not discriminative stimulus effects of morphine after brief social defeat in rats. Psychopharmacology (Berl) 104:181-186.
35. Miczek KA, Covington HEr, Nikulina EMJ, Hammer RP (2004). Aggression and defeat: persistent effects on cocaine self-administration and gene expression in peptidergic and aminergic mesocorticolimbic circuits. Neurosci Biobehav Rev 27:787-802.
36. Mitchell PJ (2005). Antidepressant treatment and rodent aggressive behaviour. Eur J Pharmacol 526:147-162.
37. Muscat R, Papp M, Willner P (1992). Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology (Berl) 109:433-438.
38. Nagatani T, Sugihara T, Kodaira R (1984). The effect of diazepam and of agents which change GABAergic functions in immobility in mice. Eur J Pharmacol 97:271-275.
39. Nishimura H, Ida Y, Tsuda A, Tanaka M (1989). Opposite effects of diazepam and beta-CCE on immobility and straw-climbing behavior of rats in a modified forced-swim test. Pharmacol Biochem Behav 33:227-231.
40. Ogawa N, Mizuno S, Mori A, Nukina I, Ota Z, Yamamoto M (1984). Potential antidepressive effects of thyrotropin releasing hormone (TRH) and its analogues. Peptides 5:743-746.
41. Orsetti M, Colella L, Dellarole A, Canonico PL, Ferri S, Ghi P (2006). Effects of chronic administration of olanzapine, amitriptyline, haloperidol or sodium valproate in naive and anhedonic rats. Int J Neuropsychopharmacol 9: 427-436.
42. Papp M,Willner P, Muscat R (1991). An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology (Berl) 104:255-259.
43. Papp M, Moryl E,Willner P (1996). Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 296:129-136.
44. Patacchioli FR, Di Grezia R, Angelucci L (1996). Arginine-aspartate and haloperidol-induced neurobehavioral effects in the rat. Eur J Pharmacol 299:29-32.
45. Paulus MP, Geyer MA (1991). A scaling approach to find order parameters quantifying the effects of dopaminergic agents on unconditioned motor activity in rats. Prog Neuropsychopharmacol Biol Psychiatry 15:903-919.
46. Pellow S, Chopin P, File SE, Briley M (1985). Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-167.
47. Phillipson OT (1979). Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: a horseradish peroxidase study in the rat. J Comp Neurol 187:117-143.
48. Porsolt RD (1979). Animal model of depression. Biomedicine 30:139-140.
49. Porsolt RD, Anton G, Blavet N, Jalfre M (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379-391.
50. Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A (2003). Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 160:297-302.
51. Rauhut AS, Mullins SN, Dwoskin LP, Bardo MT (2002). Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Ther 303:664-672.
52. Rodgers RJ, Dalvi A (1997). Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 21:801-810.
53. Rupniak NM, Jenner P, Marsden CD (1986). Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl) 88:403-419.
54. Rygula R, Abumaria N, Flugge G, Fuchs E, Ruther E, Havemann-Reinecke U (2005). Anhedonia and motivational deficits in rats: impact of chronic social stress. Behav Brain Res 162:127-134.
55. Rygula R, Abumaria N, Domenici E, Hiemke C, Fuchs E (2006a). Effects of fluoxetine on behavioral deficits evoked by chronic social stress in rats. Behav Brain Res 174:188-192.
56. Rygula R, Abumaria N, Flugge G, Hiemke C, Fuchs E, Ruther E, Havemann-Reinecke U (2006b). Citalopram counteracts depressive-like symptoms evoked by chronic social stress in rats. Behav Pharmacol 17:19-29.
57. Schmitt U, Dahmen N, Fischer V, Weigmann H, Rao ML, Reuss S, Hiemke C (1999). Chronic oral haloperidol and clozapine in rats: a behavioral evaluation. Neuropsychobiology 39:86-91.
58. Seligman LD, Ollendick TH (1998). Comorbidity of anxiety and depression in children and adolescents: an integrative review. Clin Child Fam Psychol Rev 1:125-144.
59. Shaldubina A, Einat H, Szechtman H, Shimon H, Belmaker RH (2002). Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm 109:433-440.
60. Shephard RA, Nielsen EB, Broadhurst PL (1982). Sex and strain differences in benzodiazepine receptor binding in Roman rat strains. Eur J Pharmacol 77:327-330.
61. Steru L, Chermat R, Thierry B, Mico JA, Lenegre A, Steru M, Simon P, et al. (1987). The automated Tail Suspension Test: a computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatry 11:659-671.
62. Tamborska E, Insel T, Marangos PJ (1986). 'Peripheral' and 'central' type benzodiazepine receptors in Maudsley rats. Eur J Pharmacol 126:281-287
63. Vaccheri A, Dall'Olio R, Gaggi R, Gandolfi O, Montanaro N (1984). Antidepressant versus neuroleptic activities of sulpiride isomers on four animal models of depression. Psychopharmacology (Berl) 83:28-33.
64. van den Buuse M, de Jong W (1989). Differential effects of dopaminergic drugs on open-field behavior of spontaneously hypertensive rats and normotensive Wistar-Kyoto rats. J Pharmacol Exp Ther 248:1189-1196.
65. Van der Meersch-Mougeot V, da Rocha M Jr, Monier C, Diquet B, Puech AJ, Thiebot MH (1993). Benzodiazepines reverse the anti-immobility effect of antidepressants in the forced swimming test in mice. Neuropharmacology 32:439-446.
66. Weiner I, Schiller D, Gaisler-Salomon I, Green A, Joel D (2003). A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine. Behav Pharmacol 14:215-222.
67. Willner P, Mitchell PJ (2002). The validity of animal models of predisposition to depression. Behav Pharmacol 13:169-188.
68. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R (1987). Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 93:358-364.
69. Willner P, D'Aquila PS, Coventry T, Brain P (1995). Loss of social status: preliminary evaluation of novel animal model of depression. J Psychopharmacol 9:207-213.
70. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, Hyslop DK, et al. (2000). Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47:818-829.
71. Zhang Y, Xu H, He J, Yan B, Jiang W, Li X, Li XM (2007). Quetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatment. Neurosci Lett 420:66-71.